Vor Biopharma (VOR) Stock Forecast & Price Target

Compare

880 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VOR Analyst Ratings

Moderate Buy

2 Buy

5 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Vor

Biopharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VOR Stock 12 Month Forecast

Average Price Target

$1.18

▼(-50.42%Downside)

Based on 7 Wall Street analysts offering 12 month price targets for Vor Biopharma in the last 3 months. The average price target is $1.18 with a high forecast of $3.00 and a low forecast of $0.30. The average price target represents a -50.42% change from the last price of $2.38.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Aug<br/>2024","9":"Dec<br/>2024","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.23,0.4430769230769231,0.6561538461538462,0.8692307692307693,1.0823076923076924,1.2953846153846154,1.5084615384615385,1.7215384615384615,1.9346153846153846,2.147692307692308,2.3607692307692307,2.5738461538461537,2.786923076923077,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.23,0.3030769230769231,0.37615384615384617,0.4492307692307692,0.5223076923076923,0.5953846153846153,0.6684615384615384,0.7415384615384615,0.8146153846153845,0.8876923076923076,0.9607692307692306,1.0338461538461539,1.106923076923077,{"y":1.18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.23,0.2353846153846154,0.24076923076923076,0.24615384615384617,0.25153846153846154,0.2569230769230769,0.2623076923076923,0.2676923076923077,0.27307692307692305,0.2784615384615384,0.28384615384615386,0.28923076923076924,0.2946153846153846,{"y":0.3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.22,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.23,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$3.00

Average Price Target$1.18

Lowest Price Target$0.30

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Swayampakula RamakanthH.C. Wainwright

H.C. Wainwright

Buy

26.05%

Upside

Upgraded

06/30/25

Vor Biopharma's Strategic Licensing and Growth Potential Justifies Buy Rating

David NierengartenWedbush

Wedbush

$0.4

Hold

-83.19%

Downside

Reiterated

06/26/25

Wedbush Reaffirms Their Hold Rating on Vor Biopharma (VOR)

Stephen WilleyStifel Nicolaus

Stifel Nicolaus

$0.3

Hold

-87.39%

Downside

Reiterated

06/26/25

Stifel Nicolaus Keeps Their Hold Rating on Vor Biopharma (VOR)

Jack AllenRobert W. Baird

Robert W. Baird

$0.25→$1

Hold

-57.98%

Downside

Reiterated

06/26/25

Vor Biopharma (VOR) Gets a Hold from Robert W. Baird

Umer RaffatEvercore ISI

Evercore ISI

―

Buy

―

Reiterated

05/12/25

Vor Biopharma (VOR) Receives a Buy from Evercore ISI

Silvan TuerkcanCitizens JMP

Citizens JMP

―

Hold

―

Downgraded

05/09/25

Vor Bio downgraded to Market Perform from Outperform at Citizens JMPVor Bio downgraded to Market Perform from Outperform at Citizens JMP

Justin WalshJonesTrading

JonesTrading

―

Hold

―

Downgraded

05/08/25

JonesTrading downgrades Vor Biopharma (VOR) to a Hold

Matthew BieglerOppenheimer

Oppenheimer

Buy

236.13%

Upside

Reiterated

12/09/24

Vor Bio trem-cel relapse-rate remains low, says OppenheimerVor Bio trem-cel relapse-rate remains low, says Oppenheimer

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Swayampakula RamakanthH.C. Wainwright

H.C. Wainwright

Buy

26.05%

Upside

Upgraded

06/30/25

Vor Biopharma's Strategic Licensing and Growth Potential Justifies Buy Rating

David NierengartenWedbush

Wedbush

$0.4

Hold

-83.19%

Downside

Reiterated

06/26/25

Wedbush Reaffirms Their Hold Rating on Vor Biopharma (VOR)

Stephen WilleyStifel Nicolaus

Stifel Nicolaus

$0.3

Hold

-87.39%

Downside

Reiterated

06/26/25

Stifel Nicolaus Keeps Their Hold Rating on Vor Biopharma (VOR)

Jack AllenRobert W. Baird

Robert W. Baird

$0.25→$1

Hold

-57.98%

Downside

Reiterated

06/26/25

Vor Biopharma (VOR) Gets a Hold from Robert W. Baird

Umer RaffatEvercore ISI

Evercore ISI

―

Buy

―

Reiterated

05/12/25

Vor Biopharma (VOR) Receives a Buy from Evercore ISI

Silvan TuerkcanCitizens JMP

Citizens JMP

―

Hold

―

Downgraded

05/09/25

Vor Bio downgraded to Market Perform from Outperform at Citizens JMPVor Bio downgraded to Market Perform from Outperform at Citizens JMP

Justin WalshJonesTrading

JonesTrading

―

Hold

―

Downgraded

05/08/25

JonesTrading downgrades Vor Biopharma (VOR) to a Hold

Matthew BieglerOppenheimer

Oppenheimer

Buy

236.13%

Upside

Reiterated

12/09/24

Vor Bio trem-cel relapse-rate remains low, says OppenheimerVor Bio trem-cel relapse-rate remains low, says Oppenheimer

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vor Biopharma

1 Month

xxx

Success Rate

6/13 ratings generated profit

Average Return

+2.68%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 46.15% of your transactions generating a profit, with an average return of +2.68% per trade.

3 Months

xxx

Success Rate

6/16 ratings generated profit

Average Return

-13.50%

upgraded a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 37.50% of your transactions generating a profit, with an average return of -13.50% per trade.

1 Year

Matthew BieglerOppenheimer

Success Rate

2/13 ratings generated profit

Average Return

-28.62%

reiterated a buy rating 7 months ago

Copying Matthew Biegler's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -28.62% per trade.

2 Years

xxx

Success Rate

5/13 ratings generated profit

Average Return

-17.57%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 38.46% of your transactions generating a profit, with an average return of -17.57% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VOR Analyst Recommendation Trends

Rating

Nov 24

Dec 24

Mar 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VOR has received 6 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. VOR average Analyst price target in the past 3 months is 1.18.

Each month's total comprises the sum of three months' worth of ratings.

VOR Financial Forecast

VOR Earnings Forecast

Next quarter’s earnings estimate for VOR is -$0.44 with a range of -$1.25 to -$0.17. The previous quarter’s EPS was -$0.25. VOR beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.43% of the time in the same period. In the last calendar year VOR has Outperformed its overall industry.

No data currently available

VOR Sales Forecast

Next quarter’s sales forecast for VOR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. VOR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.77% of the time in the same period. In the last calendar year VOR has Preformed in-line its overall industry.

VOR Stock Forecast FAQ

What is VOR’s average 12-month price target, according to analysts?

Based on analyst ratings, Vor Biopharma’s 12-month average price target is 1.18.

What is VOR’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for VOR, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VOR a Buy, Sell or Hold?

Vor Biopharma has a consensus rating of Moderate Buy which is based on 2 buy ratings, 5 hold ratings and 0 sell ratings.

What is Vor Biopharma’s price target?

The average price target for Vor Biopharma is 1.18. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $3.00 ,the lowest forecast is $0.30. The average price target represents -50.42% Decrease from the current price of $2.38.

What do analysts say about Vor Biopharma?

Vor Biopharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of VOR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Vor Biopharma (VOR) Stock Forecast & Price Target

VOR Analyst Ratings

VOR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vor Biopharma

VOR Analyst Recommendation Trends

VOR Financial Forecast

VOR Earnings Forecast

VOR Sales Forecast

VOR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts